Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Change in Inventory (2020 - 2025)

Historic Change in Inventory for Sanara MedTech (SMTI) over the last 9 years, with Q3 2025 value amounting to -$8278.0.

  • Sanara MedTech's Change in Inventory rose 9819.9% to -$8278.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 17014.04%. This contributed to the annual value of -$1.4 million for FY2024, which is 19336.1% down from last year.
  • Sanara MedTech's Change in Inventory amounted to -$8278.0 in Q3 2025, which was up 9819.9% from $525147.0 recorded in Q2 2025.
  • Sanara MedTech's Change in Inventory's 5-year high stood at $1.0 million during Q2 2023, with a 5-year trough of -$500149.0 in Q2 2024.
  • Over the past 5 years, Sanara MedTech's median Change in Inventory value was $65433.0 (recorded in 2022), while the average stood at $152322.5.
  • As far as peak fluctuations go, Sanara MedTech's Change in Inventory surged by 247483.79% in 2023, and later crashed by 35301.38% in 2024.
  • Quarter analysis of 5 years shows Sanara MedTech's Change in Inventory stood at $640844.0 in 2021, then tumbled by 89.79% to $65433.0 in 2022, then plummeted by 282.44% to -$119375.0 in 2023, then rose by 24.76% to -$89821.0 in 2024, then soared by 90.78% to -$8278.0 in 2025.
  • Its last three reported values are -$8278.0 in Q3 2025, $525147.0 for Q2 2025, and $605628.0 during Q1 2025.